Venetoclax & CLL: Hope for Older Adults
- A recent study indicates that venetoclax, a BCL-2 inhibitor, demonstrates critically important efficacy in treating elderly patients with chronic lymphocytic leukemia (CLL).The research, featured in Blood Advances, emphasizes...
- The study, conducted across 23 Italian medical centers, involved 120 patients over 80 years old.
- Researchers, including Livio Trentin, MD, of the University of Padova in Italy, noted that while CLL predominantly affects older adults-the median age at diagnosis is 70, according to...
Venetoclax shows significant promise for elderly patients battling chronic lymphocytic leukemia (CLL), according to a recent study. Researchers found a remarkable 91% overall response rate, offering a beacon of hope for older adults often excluded from clinical trials. The study emphasizes the importance of tailored treatment management due to potential side effects such as neutropenia and infections. Discover how the efficacy of this primary_keyword, venetoclax, compares to BTK inhibitors, offering new insights into secondary_keyword, CLL treatment strategies. News Directory 3 brings you the latest on this and other critical medical breakthroughs. Delve deeper into understanding this BCL-2 inhibitor and its impact on older adults. Discover what’s next for CLL treatment.
Venetoclax Shows Promise for Elderly CLL Patients, Study Shows
Updated June 20, 2025
A recent study indicates that venetoclax, a BCL-2 inhibitor, demonstrates critically important efficacy in treating elderly patients with chronic lymphocytic leukemia (CLL).The research, featured in Blood Advances, emphasizes the importance of managing treatment challenges, such as temporary interruptions, in this population.
The study, conducted across 23 Italian medical centers, involved 120 patients over 80 years old. The median age of participants at the start of therapy was 81. Most patients had significant comorbidities. the research aimed to address the underrepresentation of elderly patients in clinical trials, providing clinicians with more informed treatment options for chronic lymphocytic leukemia.
Researchers, including Livio Trentin, MD, of the University of Padova in Italy, noted that while CLL predominantly affects older adults-the median age at diagnosis is 70, according to the National Institutes of Health-those over 80 are often excluded from key studies. This leaves a gap in understanding the best approaches to chronic lymphocytic leukemia treatment for this demographic.
The study found a 91% overall response rate among those treated with venetoclax, either as a monotherapy or in combination with rituximab or obinutuzumab. This rate mirrors results seen in younger patients. However, the study also noted common side effects such as neutropenia (37%) and grade 3 or higher infections (22%).
The study also highlighted the need for careful patient management. A third of patients required more than five weeks to reach the target dose of venetoclax,and 43% needed temporary treatment interruptions.
Comparing venetoclax to Bruton tyrosine kinase inhibitors (BTKis), the researchers found similar overall efficacy, though venetoclax showed a higher rate of complete responses. while BTKIs were associated with more cardiovascular toxicities (26% vs. 4%), venetoclax had a higher rate of infectious events (82% vs. 49%).
trentin and colleagues cautioned that the comparison should be interpreted carefully due to differences in patient risk profiles and the study’s retrospective nature. They concluded, however, that the findings offer valuable real-world evidence supporting the use of venetoclax-based combinations for treating chronic lymphocytic leukemia in elderly patients.
What’s next
Further research is needed to refine treatment strategies and optimize patient management for elderly patients with chronic lymphocytic leukemia, ensuring the best possible outcomes with venetoclax and othre therapies.